NCT02325050View on ClinicalTrials.gov

A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

January 8, 2015

Primary Completion Date

July 2, 2015

Study Completion Date

May 8, 2017

Conditions
Healthy
Interventions
BIOLOGICAL

MVA-BN-Filo

One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).

BIOLOGICAL

Ad26. ZEBOV

One 0.5 mL IM injection of 5\*10\^10 viral particles (vp).

BIOLOGICAL

MVA-BN-Filo

One 0.5 milliliter (ml) intramuscular (IM) injection of 4.4\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).

BIOLOGICAL

Ad26. ZEBOV

One 0.5 mL IM injection of 1\*10\^11 viral particles (vp).

OTHER

Placebo

One 0.5 mL IM injection of 0.9% saline.

Trial Locations (1)

Unknown

Rockville

All Listed Sponsors
lead

Janssen Vaccines & Prevention B.V.

INDUSTRY

NCT02325050 - A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants | Biotech Hunter | Biotech Hunter